| 16.95 0.09 (0.53%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 20.21 | 1-year : | 20.91 |
| Resists | First : | 17.31 | Second : | 17.9 |
| Pivot price | 17.15  |
|||
| Supports | First : | 16.34 | Second : | 13.59 |
| MAs | MA(5) : | 16.75 |
MA(20) : | 17.13 |
| MA(100) : | 16.53 |
MA(250) : | 14.91 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 27.6 |
D(3) : | 22.1 |
| RSI | RSI(14): 47.6 |
|||
| 52-week | High : | 17.9 | Low : | 10.88 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ HQL ] has closed above bottom band by 36.7%. Bollinger Bands are 34.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 17.13 - 17.2 | 17.2 - 17.27 |
| Low: | 16.59 - 16.66 | 16.66 - 16.74 |
| Close: | 16.83 - 16.95 | 16.95 - 17.06 |
Tekla Life Sciences Investors, a closed-ended equity mutual fund, is expertly managed by Tekla Capital Management LLC. This U.S.-domiciled fund, which commenced operations on February 20, 1992, and was formerly known as H&Q Life Sciences Investors, seeks investment opportunities in publicly traded companies worldwide. Its primary focus lies within the broad life sciences sector, encompassing a diverse range of industries such as biotechnology, pharmaceuticals, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, and medical devices and supplies. The fund also extends its investment purview to include the agriculture and environmental management sectors. It predominantly allocates capital to growth-oriented businesses, particularly those with small market capitalizations. Investment decisions are rooted in rigorous fundamental analysis, which assesses critical factors like a company's market position for its offerings, the acumen of its management team, its technological prowess, and its capability to either self-finance expansion or attract external funding to build its portfolio. The fund's performance is gauged against two key benchmarks: the NASDAQ Biotech Index and the S&P 500 Index.
Thu, 11 Jun 2026
New abrdn Life Sciences (NYSE: HQL) director files initial Form 3 - Stock Titan
Thu, 11 Jun 2026
Mahai Chris LaVictoire joins abrdn Healthcare (HQH) as reporting insider - Stock Titan
Thu, 28 Aug 2025
Abacus Global Management - ABX - Stock Price & News - The Motley Fool
Wed, 30 Sep 2020
abrdn Healthcare Investors (HQH) Stock News - Stock Titan
Wed, 30 Sep 2020
abrdn Life Sciences Investors (HQL) Stock News - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Asset Management
|
|
| Shares Out | 0 (M) |
| Shares Float | 30 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 24 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 259.39 |
| Profit Margin | 4 % |
| Operating Margin | 415.7 % |
| Return on Assets (ttm) | -346.9 % |
| Return on Equity (ttm) | -0.5 % |
| Qtrly Rev. Growth | 1.94e+006 % |
| Gross Profit (p.s.) | -94.46 |
| Sales Per Share | 23.77 |
| EBITDA (p.s.) | 2.62162e+006 |
| Qtrly Earnings Growth | 2.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 32 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0.06 |
| Price to Sales | 0.71 |
| Price to Cash Flow | 0.72 |
| Dividend | 0 |
| Forward Dividend | 21320 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|